预约演示

BeiGene finally snags FDA approval for PD-1 drug Tevimbra after long delay, Novartis breakup

2024-03-15

上市批准引进/卖出

BeiGene would have enjoyed Big Pharma support for Tevimbra from Novartis, but the two firms parted ways in September.

BeiGenemonths after the FDA’s original target deciTevimbrae on cNovartisug tislelizumab, BeiGene has finally received the U.S. go-ahead.

The PD-1 inhibitor now cFDAies the brand name Tevimbra. It’s apcancer to trtislelizumab esophageal squamous cell carcinoma after prior systemic chemotherapy, BeiGene said Thursday. Patients won’t be eligible for the drug if they have previously received a PD-1/L1 inhibitor.

The PD-1 inhibitor PD-1was originally scheduled to deliver a Tevimbraon the drug in July 2022,advanced esophageal squamous cell carcinomaupted that plan because the agency wasn’t able to perform preapproval inspections in China. Tevimbra secured its initial approval in CPD-1/L1 inhibitor PD-1/L1 December 2019 for previously treated classical Hodgkin lymphoma.

TeviFDAa isn’t the first PD-1 drug to reach esophageal cancer. Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo are both approved here.classical Hodgkin lymphoma

Tevimbrawould have enjoyePD-1 drugrma commeresophageal cancerrtMerck & Co.ra KeytrudaartisBristol Myers SquibbparOpdivoys in September, with Novartis citing a changing PD-1 inhibitor landscape as its rationale. Novartis will still help manufacture Tevimbra.

BeiGenethe breakup, Novartis in 2022 decided not to file Tevimbra asTevimbraherapyNovartisly diagnosed non-small cell lung cancer (NSCLC) in Novartis The decision came PD-1he FDA cracked down on China-only data Novartisn’t reflect the treatment lanTevimbran the U.S.

Amid BeiGene’s regulNovartislay, Coherus BioSciences and Tevimbraiosciences-partnered Loqtorzi became tnon-small cell lung cancer (NSCLC) to reach the U.S. market with two indFDAtions in nasopharyngeal carcinoma.

Amid BeiGenepproval is based on tCoherus BioSciencesial, Junshi Biosciencesne drug slaLoqtorzi risk of death by 30% comparePD-1th chemotherapy. Patients on Tevimbra lived a median 8.6 monnasopharyngeal carcinomaor those who received traditional chemo.

The European Commission in September approved Tevimbra for the same post-chemo esophageal cancer indication.Tevimbra

BeiGene won’t launch Tevimbra immediately, sayTevimbraill make the drug availabesophageal cancer the second half of 2024. The company also hasn’t launched the drug in Europe as it waits for a final European Commission approval for three NSCLC indications.

BeiGene is reviewing TevimbraTevimbra application in first-line esophageal cancer, with a decision expected in July. A BeiGene spokesperson declined to comment on whether the company is holding off the rollout until the first-line decisiNSCLC

BeiGFDA will share Tevimbra’sTevimbraloser to launch, the spokesesophageal cancerrus earlier this year launched LoqtorzBeiGenelist price of $8,892.03 per single-use vial, which marks a 20% discount to Keytruda.

BeiGeneGene’s first drug candidate produced through our immuno-oncology progrCoherussecond approved medicine in Loqtorzi, Tevimbra is poised to be a critical pillar of our solid tumor development progrKeytrudak Lanasa, M.D. Ph.D., BeiGene’s chief medical officer of solid tumors, said in a statement Thursday.

WithBeiGenele indications in China, Tevimbra grew sales by 27% year over year in 2023 to reach $537 million in 2023.Tevimbra solid tumor BeiGene solid tumors

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构